Panitumumab in combination with cytotoxic chemotherapy for the treatment of metastatic colorectal carcinoma.

[1]  M. Yassine,et al.  Results from panitumumab (pmab) regimen evaluation in colorectal cancer to estimate primary response to treatment (PRECEPT): Second-line treatment with pmab and FOLFIRI by tumor KRAS status. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  E. Van Cutsem,et al.  Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Jorissen,et al.  Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAFV600E mutation , 2011, International journal of cancer.

[4]  H. Sorbye,et al.  Randomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: The NORDIC VII study (NCT00145314), by the Nordic Colorectal Cancer Biomodulation Group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Josep Tabernero,et al.  Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  E. Van Cutsem,et al.  Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Bardelli,et al.  Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. , 2010, JAMA.

[8]  Sabine Tejpar,et al.  Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.

[9]  I. Nagtegaal,et al.  Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. , 2010, European journal of cancer.

[10]  Tracy T Batchelor,et al.  Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. , 2010, Neuro-oncology.

[11]  J. Tabernero,et al.  Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared to FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): PRIME trial analysis by epidermal growth factor receptor (EGFR) tumor staining. , 2010 .

[12]  J. Jassem,et al.  Randomized, open-label, phase III study of panitumumab (pmab) with FOLFOX4 versus FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST). , 2010 .

[13]  R. Greil,et al.  Panitumumab (pmab) with FOLFIRI as first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Resections and curative surgery in a phase II single arm, multicenter study (20060314). , 2010 .

[14]  J. Hartmann,et al.  Randomized, open-label, phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST). , 2010 .

[15]  A. Santoro,et al.  Randomized phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis by tumor epidermal growth factor receptor (EGFR) staining. , 2010 .

[16]  M. Tzardi,et al.  BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients’ outcome , 2010, British Journal of Cancer.

[17]  H. Lenz,et al.  Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer. , 2010, Gastroenterology.

[18]  M. Diodoro,et al.  Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab , 2010, Journal of Translational Medicine.

[19]  Y. Humblet,et al.  Abstract LB-174: Use of massively parallel, next-generation sequencing to identify gene mutations beyondERASthat predict response to panitumumab in a randomized, phase 3, monotherapy study of metastatic colorectal cancer (mCRC) , 2010 .

[20]  J. Berlin,et al.  Lack of Correlation between Epidermal Growth Factor Receptor Status and Response to Panitumumab Monotherapy in Metastatic Colorectal Cancer , 2010, Clinical Cancer Research.

[21]  M. Lacouture,et al.  Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. Bardelli,et al.  Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  E. Van Cutsem,et al.  Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.

[24]  J. Reid,et al.  Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Linda Mol,et al.  Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. , 2009, The New England journal of medicine.

[26]  J. Marshall,et al.  Vascular Endothelial Growth Factor plus Epidermal Growth Factor Receptor Dual Targeted Therapy in Metastatic Colorectal Cancer: Synergy or Antagonism? , 2009, Journal of oncology.

[27]  G. Pedrazzi,et al.  PTEN status in advanced colorectal cancer treated with cetuximab , 2009, British Journal of Cancer.

[28]  J. Meyerhardt,et al.  Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer , 2009, British Journal of Cancer.

[29]  N. Funel,et al.  PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  R. Greil,et al.  Epidermal growth factor receptor (EGFR) inhibitor-related skin toxicity: Review of interim data from a phase II study (20060314) of panitumumab (pmab) with FOLFIRI in the first-line treatment of metastatic colorectal cancer (mCRC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  K. Muro,et al.  A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer. , 2009, Japanese journal of clinical oncology.

[32]  E. Van Cutsem,et al.  Association of progression‐free survival, overall survival, and patient‐reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy , 2009, Cancer.

[33]  Peter Kraft,et al.  PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Francesca Molinari,et al.  PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. , 2009, Cancer research.

[35]  Seta Shahin,et al.  A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  C. Blanke.  Dual-antibody therapy in advanced colorectal cancer: gather ye rosebuds while ye may. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  C. Bokemeyer,et al.  Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  L. Mazzucchelli,et al.  Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[40]  Daniel J. Freeman,et al.  Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. , 2008, Clinical colorectal cancer.

[41]  Daniel J. Freeman,et al.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  R. Figlin,et al.  Dose and Schedule Study of Panitumumab Monotherapy in Patients with Advanced Solid Malignancies , 2008, Clinical Cancer Research.

[43]  A. Rademaker,et al.  Impact and Management of Skin Toxicity Associated with Anti-Epidermal Growth Factor Receptor Therapy: Survey Results , 2007, Oncology.

[44]  F. Cavalli,et al.  PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients , 2007, British Journal of Cancer.

[45]  M. Yasuno,et al.  PIK3CA mutation is predictive of poor survival in patients with colorectal cancer , 2007, International journal of cancer.

[46]  J. Berlin,et al.  Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer , 2007, Cancer.

[47]  J. Hecht,et al.  Panitumumab activity in metastatic colorectal cancer (mCRC) patients (pts) with low or negative tumor epidermal growth factor receptor (EGFr) levels: An updated analysis , 2007 .

[48]  Marc Peeters,et al.  Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  A. Psyrri,et al.  Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas , 2006, BMC Cancer.

[50]  E. Van Cutsem,et al.  Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  R. Wolff,et al.  Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. , 2005, Cancer research.

[52]  E. Sabo,et al.  Epidermal Growth Factor Receptor, c-MET, β-Catenin, and p53 Expression as Prognostic Indicators in Stage II Colon Cancer , 2004, Clinical Cancer Research.

[53]  G. Ayers,et al.  HER‐2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors , 2004, International journal of cancer.

[54]  Manuel Hidalgo,et al.  Developing inhibitors of the epidermal growth factor receptor for cancer treatment. , 2003, Journal of the National Cancer Institute.

[55]  A. Khorana,et al.  Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma , 2003, Cancer.

[56]  R. Labianca,et al.  Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[57]  이석호,et al.  Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study , 2001, British Journal of Cancer.

[58]  N. Goldstein,et al.  Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma , 2001, Cancer.

[59]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[60]  J. Herman,et al.  K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  C. Davis,et al.  Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. , 1999, Cancer research.

[62]  A. Norman,et al.  Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. , 1998, Journal of the National Cancer Institute.

[63]  Y. Nakamura,et al.  Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.

[64]  W. Scheithauer,et al.  An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[65]  F. Penault-Llorca,et al.  Impact of EGFR expression on colorectal cancer patient prognosis and survival. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[66]  F. Russo,et al.  EGF, TGF-a, and EGF-R in Human Colorectal Adenocarcinoma , 1998 .